- 1 Comparison of different sequencing techniques with multiplex real-
- time PCR for detection to identify SARS-CoV-2 variants of concern
- 3 Short titled: Comparison of different sequencing techniques for SARS-CoV-2
- 4 Diyanath Ranasinghe<sup>1#</sup>, Tibutius Thanesh Pramanayagam Jayadas<sup>1#</sup>, Deshni Jayathilaka<sup>1#</sup>,
- 5 Chandima Jeewandara<sup>1#</sup>, Osanda Dissanayake<sup>1</sup>, Dinuka Guruge<sup>2</sup>, Dinuka Ariyaratne<sup>1</sup>, Dumni
- 6 Gunasinghe<sup>1</sup>, Laksiri Gomes<sup>1</sup>, Ayesha Wijesinghe<sup>1</sup>, Ruwan Wijayamuni<sup>1</sup>, Gathsaurie Neelika
- 7 Malavige<sup>1\*</sup>

12

13

15

21

- <sup>9</sup> Allergy Immunology and Cell Biology Unit, Department of Immunology and Molecular
- Medicine, University of Sri Jayewardenepura, Nugegoda, Sri Lanka; <sup>2</sup> Colombo Municipal
- 11 Council, Colombo, Sri Lanka
- 14 #contributed equally
- 16 Correspondence should be addressed to:
- 17 Prof. Neelika Malavige DPhil (Oxon), FRCP (Lond), FRCPath (UK)
- 18 Allergy Immunology and Cell Biology Unit, Department of Immunology and Molecular
- 19 Medicine, Faculty of Medical Sciences, University of Sri Jayawardanapura, Sri Lanka.
- 20 Tel +94 (0) 772443193; Fax: +94 (0) 112802026, Email: gathsaurie.malavige@ndm.ox.ac.uk

## **Abstract**

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

As different SARS-CoV-2 variants emerge and with the continuous evolution of sub-lineages of the delta and other variants, it is crucial that all countries carry out sequencing of at least >1% of their infections, in order to detect emergence of variants with higher transmissibility and with ability to evade immunity. However, as many resource-poor countries are unable to sequence adequate number of viruses, we compared to usefulness of a commercially available multiplex real-time PCR assay to detect important single nucleotide polymorphisms (SNPs) associated with the variants and compared the sensitivity, accuracy and cost effectiveness of the Illumina sequencing platform and the Oxford Nanopore Technologies' (ONT) platform. 138/143 (96.5%) identified as the alpha and 36/39 (92.3%) samples identified as the delta variants due to the presence of lineage defining SNPs by the multiplex real time PCR, were assigned to the same lineage by either of the two sequencing platforms. 34/37 of the samples sequenced by ONT had <5% ambiguous bases, while 21/37 samples sequenced using the Illumina generated <15% ambiguous bases. However, the mean PHRED scores averaged at 32.35 by Illumina reads but 10.78 in ONT. Sub-consensus single nucleotide variations (SNV) were highly correlated between both platforms ( $R^2=0.79$ ) while indels showed a weaker correlation ( $R^2=0.13$ ). Although the ONT had a slightly higher error rate compared to the Illumina technology, it achieved higher coverage with a lower number of reads, generated less ambiguous bases and was significantly cheaper than Illumina sequencing technology. Key words: SARS-CoV-2; COVID-19, Illumina; Nanopore; variant PCR; Single nuclear polymorphism

# Introduction

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

Since the emergence of the SARS-CoV-2 virus two years ago, it continues to evolve giving rise to many variants with higher transmissibility and immune evasion abilities [1]. Despite a lower mutation rate of SARS-CoV-2 compared to many other RNA viruses such as HIV and influenza, [2], many SARS-CoV-2 variants of concern (VOCs) have emerged, which continue to drive the pandemic. Although the ongoing COVID-19 vaccine drive and other control measures have resulted in a reduction in the number of cases and deaths, many countries still report intense transmission rates [3]. This high rate of continued transmission of the virus is likely to give rise to new variants, which may evade immunity induced by vaccines, or may have a higher transmissibility than the dominant delta variant. This is already evident with the emergence of many delta-sub lineages [4], of which some are under investigation for higher transmissibility. In order to detect such possible new variants emerging, the WHO has recommended that all countries carry out genomic sequencing in at least 1% of their infections [5]. Although there are many sub-lineages of SARS-CoV-2 emerging [4], so far the WHO has named four SARS CoV-2 variants as variants of concern (VOC), which are they are alpha (B.1.1.7), beta (B.1.351), gamma (P.1) and delta (B.1.617.2)[5]. Even though sequencing is the gold standard to identify VOCs, it is time consuming and too expensive for many lower income and lower middle-income countries. In addition, although many developed countries sequence over 5% of their positive cases, many lower income countries are unable to sequence 1% and many sequence <0.2% [6]. Therefore, in order to carry out surveillance to monitor the current VOCs and to identify mutations of concern than may occur in such variants, cheaper and rapid methods are required that can be used in resource poor settings. The B.1.1.7 variant (alpha) was identified initially in the UK due to the changes in the SARS-CoV-2 real-time PCR results that occurred in the primers targeting the spike protein (S-drop) when using the Taq Path (Thermo Fisher Scientific Inc.)[7]. Subsequently, many multiplex real-time PCR assays were developed to identify Single Nucleotide Polymorphisms (SNPs) that associate with these four VOC such as the HV69-70del, K417N, N417T, W152C, E484K, N501Y, L452R, D614G, P681H or V1176F[8]. The combination of these different SNPs in the SARS-CoV-2 which can be

identified by multiplex real-time PCR can therefore be used to identify these four VOCs [9].

Many sequencing platforms are currently used to sequence the SARS-CoV-2 virus, which have their advantages and disadvantages [10]. Comparison of different sequencing protocols have shown that they have significant differences in sensitivity, reproducibility, and precision for detection of SNPs [11]. However, with the continued emergence and spread of new delta sub lineages, in addition to carrying out surveillance for VOCs, it is crucial to carry out whole genomic sequencing to identify variants which develop mutations of concern, that may evade immunity or may associate with higher transmissibility. However, as many lower income countries such as Sri Lanka, do not have adequate resources to carry out sequencing of >1% of the positive samples, we investigated the sensitivity and accuracy of a commercially available multiple real-time PCR assays for detection of different SNPs associated with VOCs. In addition, we compared the sensitivity, reproducibility, precision of identification SNPs and the cost of sequencing using the Illumina and Oxford Nanopore sequencing platforms.

## Materials and methods

Samples

1

2

4

5

7

8

9

10

11

14

15

16

18

19

20

21

3 Quantitative SARS-CoV-2 real-time PCR (qRT-PCR) was carried out on 190 samples of sputum

or nasopharyngeal swabs sent for diagnostic purposes to our laboratory from patients with

COVID-19. Of the 190 samples, all analysed by the multiplex real-time PCR to detect SNPs of

6 VOCs. 97 were subjected to sequencing by the Illumina platform, 57 by the Oxford nanopore

sequencing technology and 37 by both methods. Those with a cycle threshold (Ct) values of <30

were subjected to genomic sequencing and further multiplex q RT-PCR for identification of

SNPs associated with VOCs. Briefly, viral RNA was extracted using QIAamp viral RNA mini

kit (Qiagen, USA), SpinStarTM Viral Nucleic Acid Extraction kit 1.0 (ADT Biotech, Malaysia)

or FastGene RNA Viral Kit, (Nippon Genetics, Germany) according to manufacturer's

12 instructions.

Ethical approval for the study was obtained by the Ethics Review Committee of the University of

Sri Jayewardenepura.

### Multiplex qRT-PCR for identification of SNPs in VOCs

17 Multiplex qRT-PCR to detect SNPs was carried out using the SARS-COV-2 variant PCR

Allplex<sup>TM</sup> assay 1 and assay 2 in all 190 samples. The variant assay 1 detects SNPs for 501Y,

E484K and 69-70 deletion, whereas variant assay 2 detects the SNPs L452R, W152C, K417T

and K17N. The variant PCR assays were carried out according to the manufacturer's

instructions using 5µl of the extracted RNA from samples (Supplementary methods). All the

thermal cycling steps were carried out in a CFX96 Deep Well, Real time System (Bio-Rad,

2 USA).

3

5

8

9

10

11

12

13

15

16

17

18

19

20

21

Genomic sequencing using Oxford Nanopore (ONT) platform

4 The extracted RNA of 57/190 samples were subjected to nanopore sequencing according to the

manufacture's instruction using the SQK-RBK110.96 rapid barcoding kit (ONT, Oxford, UK).

6 1200 bp tiled PCR amplicons were generated with midnight primers as described in Freed et al.,

7 2020[12]. All the thermal cycling steps were carried out in a QuantStudio<sup>TM</sup> 5 Real-Time PCR

Instrument (Applied biosystems, Singapore). Barcodes were attached to resulting amplicons and

pooled together before the clean-up step. Finally, 800ng of library was loaded into R9.4.1 flow

cell and sequenced on the Oxford Nanopore Minion Mk1C. The run was stopped once desired

number of reads (~15,000 reads per sample) were achieved.

#### Genomic sequencing using the Illumina platform

14 97 were subjected to sequencing by the Illumina sequencing platform. Library preparation

Illumina sequencing was carried out using the AmpliSeq for Illumina SARS-CoV-2 Community

Panel, in combination with AmpliSeq for Illumina library prep, index, and accessories (Illumina,

San Diego, USA). The methodology is further described in supplementary methods.

### **Bioinformatics and statistical analysis**

Data from Illumina Nextseq 550 platform were base called using inbuilt bcl2fastq and the

resulting data were analyzed using the Dragen somatic pipeline on Basespace sequencing hub

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

[13]. Resulting Binary alignment files (BAM), variant call files (VCF) and consensus fasta sequences were taken further for comparison. ONT fast5 data were base called and demultiplexed using guppy version 4.4.2 occupying the fast model with a 60 single end barcode score. Resultant fastq files were analyzed using Nextflow wf-artic version v0.3.2 (https://github.com/epi2me-labs/wf-artic) with "fast\_min\_variant\_c507" model. Read length cutoff values obtained were in the range of 150bp and 1200bp, without barcode trimming. Resulting BAM, VCF and consensus fasta sequences were carried forward. Fastq and Bam statistics were generated using fastp 2 [14], Nanocomp 3 [15], samtools version 1.9 and in-house scripts. VCF data were processed using vcftools version 0.1.15 and bcftools version 1.7[16]. Multi-way pileup (mpileup) was made from ONT and Illumina alignments before analyzing with VarScan2[17] for detection of low frequency variants.

pipeline Fasta sequences through the Covsurver variant annotation were run (https://www.gisaid.org/epiflu-applications/covsurver-mutations-app/) and for lineage assessment each sequence was assessed using Pangolin version v3.1.11 [18] with the lineage version of 2021-08-09 and Serious constellations of reoccurring phylogenetically-independent origin (Scorpio) version 0.3.12 (https://github.com/cov-lineages/scorpio). All the consensus fasta sequences were aligned to the reference sequence MN908947.3 using MAFFT version 7.487 and a maximum likelihood phylogenetic tree was created using IQ-TREE version 1.6.1 [19] occupying the best fit TIM2+F+R2 model with 1000 bootstrap replicates. Raw fastq files for 74 datasets were deposited to NCBI Sequence read achieve (SRA) while the fasta sequences were uploaded to GISAID (Supplementary table 1). Plots were generated in R version 4.0.1 using ggplot2, dplyr and tidyverse.

**Results** 

1

2

4

5

6

7

8

9

12

13

14

15

16

17

18

19

20

21

3 Multiplex real-time PCR to detect SNPs of VOCs was carried out initially in 190 unblinded

samples. These 190 samples were then sequenced either on Illumina or ONT (depending on the

availability of sequencing reagents) to evaluate the accuracy of the variant PCR. 37/190 of the

samples were sequenced with both the Illumina and ONT platforms to compare the quality and

accuracy of the data generated by these two platforms.

Comparison between next generation sequencing with multiplex real-time PCR assays for

10 detection of SNP (variant PCR assay)

11 143/190 samples were positive for the SNPs N501Y and HV69/70 deletion in the spike protein

by the multiplex PCR and therefore, considered to be as B.1.1.7. The samples in which these two

SNPs were not detected (n=47) were re-screened using the variant assay 2, which detected the

SNPs L452R, W152C, K417T and K17N. Based on the results of the variant assay 2, 39 samples

were positive only for the spike L452R mutation and were therefore, considered to be B.1.617.

One sample with spike K417N mutation along with N501Y and HV69/70 deletion from the

assay was considered to be B.1.351. 7/190 samples were not assigned to be any VOC as they did

not have any of the SNPs associated with the VOCs.

138/143 (96.5%) of the sample which were considered to be B.1.1.7 by variant PCR assay were

also assigned the same Pangolin lineage based on the sequencing by either sequencing platforms.

1 The remaining 5/143 could not be assigned to a lineage, due to the low sequencing coverage.

3/39 samples which were considered to be B.1.617 due to the presence of the SNP spike L452R,

were re-classified into C.36 lineage, while the rest (36/39) were classified into Pangolin lineage

B.1.617.2 (92.3%). 7/7 samples in which the SNPs were not detected, were classified into either

B.1, B.1.1 or B.1.411 (Supplementary table 2). Of the 305/332 individual mutations detected by

the variant PCR assay were confirmed by at least one of the sequencing methods. Rest of the

unconfirmed spike mutations were masked by N bases in the consensus sequences due to either

low coverage or base call accuracy.

### **Comparison between Illumina and ONT sequencing platforms**

### Sequencing statistics

2

3

4

5

6

7

8

9

10

11

13

14

15

16

17

18

19

20

21

22

12 37 SARS-CoV-2 samples sequenced using both approaches had more than 45% of the genome

coverage and were included in the analysis for comparison of both techniques. Ampliseq SARS-

CoV-2 primers used for Illumina library contained 247 amplicons in 2 pools covering >99% of

the genome (reference positions between 30 to 29842). The Midnight primer scheme used in the

ONT, with just 29 primers in two pools created 1200bp long amplicons and typically covered 54

to 29903 positions. The 150bp Illumina library yielded ~50 million bases, whereas 1200bp ONT

library yielded only ~9 million. However, despite the lower number of reads with ONT, it was

able to achieve twice the coverage depth of which was achieved by the Illumina platform (Table

1). With the Illumina sequencing technology, the samples required an average of 372,654 reads

per sample, whereas ONT achieved even higher coverage depth with an average 9741 reads per

sample due to its ability to score ultra-long reads. The higher proportion of ambiguous bases

generated by the Illumina platform, resulted in non-detection of several mutations in each

sample. We observed one consistent amplicon drop at third amplicon in ONT dataset due to

K634N mutation in ORF1a, which is prevalent in Sri Lankan delta sub-lineage,

4 B.1.617.2.AY.28.

1

2

3

5

8

9

10

11

13

14

16

17

18

19

20

21

22

6 Illumina raw reads had an average PHRED quality score (probability of error per base call in a

7 log scale) of 32.35 with a highest score of 36 which is between 1 in 1000 to 1 in 10,000

probability of calling an incorrect base (99.9 – 99.99% accuracy). ONT on the other hand had

recorded an average score of 10.78 with a 16.2 highest PHRED quality score indicating between

1 in 10 to 1 in 100 probability of error (90% - 99% accuracy). This explains the average identity

to the reference genome of 99.6% in Illumina reads and 91.4% in ONT reads (Table 1 and Figure

12 1).

#### Consensus accuracy

15 We used iVar [20] and Medaka workflows to call consensus for Illumina and ONT respectively.

ONT detected more average mutations per sample compared to Illumina (36 vs 31) and majority

of them were non-synonymous mutations scoring average of 22 and 25 amino acid substitutions

in Illumina and ONT respectively. Some known amino acid mutations such as Spike N501Y and

NSP12 P323L were constantly missed in Illumina consensus sequences which was caused by

masking of those regions due to drop of coverage (Figure 2). However, average number of

deletions per sample were between 14 to 15 range for both approaches (Figure 3). Average

percentage of ambiguous (N) bases was higher in Illumina sequences compared to ONT (9% vs

1 6%), whereas samples with less than 10% ambiguous bases were higher for ONT compared to

Illumina (29 vs 25). The ONT consensus sequences had 2 frameshift mutations at nucleotide

positions of 1634 and 21992, whereas no frameshift mutations were found in the Illumina

4 dataset.

2

3

5

6

7

8

9

10

11

12

13

15

16

17

18

19

20

21

22

Due to improved coverage over the SARS-CoV-2 genome, more samples which were sequenced

using the ONT platform were lineage call-able by both Pango and Scorpio nomenclature. Pango

lineage calls of 16/37 were identical in both platforms while 7/37 lineage calls were different

between the two sequencing platforms. Two B.1.1.7 lineage calls were classified as B.1.1 in

Illumina dataset and the remaining 5 calls were different only at the sub-lineage level

(Supplementary table 2). In the combined phylogenetic tree of consensus sequences, 28/37

samples paired with their counterpart sequences, while those that were not paired together had

moderate to high (3% - 31%) ambiguous bases in one of the counterpart sequences. Higher than

98% bootstrap support can be observed in 21/37 samples which had > 90% genome coverage

14 from both sequencing technologies (Figure 4).

### Intra-sample variation

We further analyzed BAM alignments using VarScan2 to determine the rate of both consensus

and sub-consensus variants between two technologies. Collectively, 191 single nucleotide

variants (SNVs) and 9 indels were detected in the read pileup of Illumina dataset, while 226

SNVs and 304 indels were detected in ONT read pileup. However, 175 SNVs were concordant

across both datasets suggesting they are true variants. 15 SNVs detected only in the Illumina

dataset are of very low allele frequency (5%-0.1%) whereas 51 SNVs detected only in the ONT

dataset are of allele frequency ranging between 52%-0.1% (Supplementary table 2). 8 indels

were concordant between both platforms while a significant number (296) of false positive indels

were detected in the ONT dataset with allele frequency between 52% - 0.1%. We also observed a

strong correlation between the SNV frequencies (R<sup>2</sup>=0.79) between the two platforms, while

there was a weak correlation between indel frequencies ( $R^2=0.13$ ) of Illumina and ONT datasets

6 (Figure 5).

2

3

4

5

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

# Discussion

In this study we compared the accuracy and sensitivity of a commercial multiple real-time PCR assay for detection of different SNPs with two sequencing technologies in identifying SARS-CoV-2 VOCs. 190 samples which were tested by the variant PCR technique showed 100% concordance with the results of either Illumina or ONT sequencing platforms as far as the VOC assignment. However, 3 samples which were considered to be B.1.617 due to the presence of the SNP L452R, were assigned to the C.36 Pangolin lineage following sequencing. Since there are many variants with the L452R [21], when multiple SARS-CoV-2 variants are co-circulating, classifying a virus into the B.1.617 lineage based on the L452R mutation alone, would result in inaccuracies. However, for the SNPs E484K, K417T, L452R, K417N, W152C and 69/70 deletion no false positive or false negatives were detected. Therefore, the VOCs assigned to either B.1.1.7 or B.1.351 showed 100% accuracy with both sequencing platforms. Therefore, the variant PCR appears to be a relatively inexpensive and rapid technique to carry out surveillance for SARS-CoV-2 variants in resource poor settings. However, with the dominance of the delta variant globally [22], these variant PCR assays have limited value in detection of new mutations of concern arising in the delta variant that may give rise to higher transmissibility and immune evasion.

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

In this study we also compared to accuracy and ease of use of two sequencing platforms. The ONT rapid barcoding workflow occupies transposase-based library preparation, which does not require individual sample washes and allows samples to be processed uniformly without quantification or normalization [23]. For Illumina, traditional ligation-based library preparation was used which required extended preparation time and effort. Run time per 96 samples on ONT is nearly half the time required for Illumina (14 hours compared to 26 hours) mainly due to the ability of real-time data analysis with ONT. The rapid barcoding library preparation method used for the ONT platform also required less reagents and therefore, was cheaper than Illumina sequencing. Although the single ended barcoding of the transposase-based libraries is thought to result in improper demultiplexing and sample crossover, it has shown to rarely affect variant calling and consensus generation in ONT [12]. The Illumina sequencing produced ~200bp long amplicons, whereas the ONT sequencing platform produced 1200bp. The long amplicons generated by the ONT sequencing achieved higher coverage and less ambiguous bases even with 10,000 reads (after filtering). As a result of this, certain mutations were not detected by the Illumina platform due to a larger proportion of ambiguous bases. For instance, 34/37 of the ONT samples had < 5% ambiguous bases while 29/37 samples sequenced using Illumina generated <15% ambiguous bases. However, the mean PHRED scores averaged at 32.35 in Illumina reads but 10.78 in ONT. This difference results in a base call error probability of 1 in 10 by the ONT and 1 in 1000 for Illumina sequencing platform. The reduced accuracy in base calls and increase the frequency of erroneous bases can be minimized by using high accuracy or super accuracy models of guppy basecaller[24]. Therefore,

1 ONT sequencing detected more nucleic acid and amino acid substitutions compared to Illumina,

possibly due to the improved coverage. While short read sequencing is considered as the gold

standard for sequencing of viral genomes [25], despite ONT having a slightly higher error rate,

ONT appears to generate high quality data at a very affordable cost. Therefore, ONT appears to

be the most cost effective, high throughout sequencing technology, especially suited for

countries with limited resources for genomic surveillance and for identification of emerging

variants of concern.

2

3

4

5

6

7

8

9

11

12

13

14

15

16

17

18

19

21

# **Conclusions**

We have compared the usefulness, accuracy and reliability of two sequencing technologies and

also compared the usefulness of a commercial multiplex real-time PCR for surveillance of

VOCs, by identification of SNPs associated with the VOCs. We found that the multiplex real-

time PCR assay detected the alpha variant with 96.5% accuracy (5/147 could not be confirmed

due to low coverage by NGS) and the delta variant with 92.3% accuracy, when compared with

either sequencing technology. Although the ONT had a slightly higher error rate compared to the

Illumina technology, it achieved higher coverage with a lower number or reads, generated less

ambiguous bases and was significantly cheaper than Illumina sequencing technology.

# **Funding information**

World Health Organization; World bank, Sri Lanka Covid 19 Emergency Response and Health

Systems Preparedness Project (ERHSP) of Ministry of Health Sri Lanka funded by World Bank.

### **Conflicts of interest**

1

2

4

5

3 None of the authors have any conflicts of interest.

# References

- 6 1. Dyson L, Hill EM, Moore S, Curran-Sebastian J, Tildesley MJ, Lythgoe KA, et al.
- 7 Possible future waves of SARS-CoV-2 infection generated by variants of concern with a range of
- 8 characteristics. Nat Commun. 2021;12(1):5730. Epub 2021/10/02. doi: 10.1038/s41467-021-
- 9 25915-7. PubMed PMID: 34593807; PubMed Central PMCID: PMCPMC8484271.
- 10 2. Luo R, Delaunay-Moisan A, Timmis K, Danchin A. SARS-CoV-2 biology and variants:
- anticipation of viral evolution and what needs to be done. Environ Microbiol. 2021;23(5):2339-
- 12 63. Epub 2021/03/27. doi: 10.1111/1462-2920.15487. PubMed PMID: 33769683; PubMed
- 13 Central PMCID: PMCPMC8251359.
- 14 3. Coronavirus Pandemic (COVID-19) [Internet]. OurWorldInData.org. 2021 [cited 28th
- June 2021]. Available from: https://ourworldindata.org/coronavirus.
- 4. Alaa Abdel Latif JLM, Manar Alkuzweny, Ginger Tsueng, Marco Cano, Emily Haag,
- 17 Jerry Zhou, Mark Zeller, Emory Hufbauer, Nate Matteson, Chunlei Wu, Kristian G. Andersen,
- Andrew I. Su, Karthik Gangavarapu, Laura D. Hughes. Global variant report: Center for Viral
- 19 Systems Biology; 2021 [cited 2021 7th November 2021]. Available from:
- 20 https://outbreak.info/location-reports?loc=LKA.

- 1 5. WHO. Guidance for surveillance of SARS-CoV-2 variants: Interim guidance, 9 August
- 2 2021. WHO Headquarters (HQ): 2021 9th August 2021. Report No.: WHO/2019-
- 3 nCoV/surveillance/variants/2021.1.
- 4 6. SARS-CoV-2 sequence entries with complete collection date information shared via
- 5 GISAID [Internet]. 2021 [cited 13 September 2021]. Available from:
- 6 https://www.gisaid.org/test5/submission-tracker-global/.
- 7. Borges V, Sousa C, Menezes L, Goncalves AM, Picao M, Almeida JP, et al. Tracking
- 8 SARS-CoV-2 lineage B.1.1.7 dissemination: insights from nationwide spike gene target failure
- 9 (SGTF) and spike gene late detection (SGTL) data, Portugal, week 49 2020 to week 3 2021.
- 10 Euro Surveill. 2021;26(10). Epub 2021/03/13. doi: 10.2807/1560-7917.ES.2021.26.10.2100130.
- PubMed PMID: 33706862; PubMed Central PMCID: PMCPMC7953529.
- 12 8. WHO. Methods for the detection and identification of SARS-CoV-2 variants, March
- 2021. World Health Organization. Regional Office for Europe.: 2021 WHO/EURO:2021-2148-
- 14 41903-57493.
- 15 9. Harper H, Burridge A, Winfield M, Finn A, Davidson A, Matthews D, et al. Detecting
- 16 SARS-CoV-2 variants with SNP genotyping. PloS one. 2021;16(2):e0243185. Epub 2021/02/25.
- doi: 10.1371/journal.pone.0243185. PubMed PMID: 33626040; PubMed Central PMCID:
- 18 PMCPMC7904205 This does not alter our adherence to PLOS ONE policies on sharing data and
- materials. All remaining authors have declared that no competing interests exist.
- 20 10. Hourdel V, Kwasiborski A, Baliere C, Matheus S, Batejat CF, Manuguerra JC, et al.
- 21 Rapid Genomic Characterization of SARS-CoV-2 by Direct Amplicon-Based Sequencing
- 22 Through Comparison of MinION and Illumina iSeq100(TM) System. Front Microbiol.

- 1 2020;11:571328. Epub 2020/10/27. doi: 10.3389/fmicb.2020.571328. PubMed PMID:
- 2 33101244; PubMed Central PMCID: PMCPMC7546329.
- 3 11. Liu T, Chen Z, Chen W, Chen X, Hosseini M, Yang Z, et al. A benchmarking study of
- 4 SARS-CoV-2 whole-genome sequencing protocols using COVID-19 patient samples. iScience.
- 5 2021;24(8):102892. Epub 2021/07/27. doi: 10.1016/j.isci.2021.102892. PubMed PMID:
- 6 34308277; PubMed Central PMCID: PMCPMC8294598.
- 7 12. Freed NE, Vlkova M, Faisal MB, Silander OK. Rapid and inexpensive whole-genome
- 8 sequencing of SARS-CoV-2 using 1200 bp tiled amplicons and Oxford Nanopore Rapid
- 9 Barcoding. Biol Methods Protoc. 2020;5(1):bpaa014. Epub 2020/10/09. doi:
- 10 10.1093/biomethods/bpaa014. PubMed PMID: 33029559; PubMed Central PMCID:
- 11 PMCPMC7454405.
- 12 13. Illumina. BaseSpace Sequence Hub. 2021.
- 13 14. Chen S, Zhou Y, Chen Y, Gu J. fastp: an ultra-fast all-in-one FASTQ preprocessor.
- 14 Bioinformatics. 2018;34(17):i884-i90. Epub 2018/11/14. doi: 10.1093/bioinformatics/bty560.
- 15 PubMed PMID: 30423086; PubMed Central PMCID: PMCPMC6129281.
- 16 15. De Coster W, D'Hert S, Schultz DT, Cruts M, Van Broeckhoven C. NanoPack:
- visualizing and processing long-read sequencing data. Bioinformatics. 2018;34(15):2666-9.
- 18 Epub 2018/03/17. doi: 10.1093/bioinformatics/bty149. PubMed PMID: 29547981; PubMed
- 19 Central PMCID: PMCPMC6061794.
- 20 16. Danecek P, Auton A, Abecasis G, Albers CA, Banks E, DePristo MA, et al. The variant
- 21 call format and VCFtools. Bioinformatics. 2011;27(15):2156-8. doi:
- 22 10.1093/bioinformatics/btr330. PubMed PMID: 21653522; PubMed Central PMCID:
- 23 PMCPMC3137218.

- 1 17. Koboldt DC, Zhang Q, Larson DE, Shen D, McLellan MD, Lin L, et al. VarScan 2:
- 2 somatic mutation and copy number alteration discovery in cancer by exome sequencing. Genome
- 3 Res. 2012;22(3):568-76. Epub 2012/02/04. doi: 10.1101/gr.129684.111. PubMed PMID:
- 4 22300766; PubMed Central PMCID: PMCPMC3290792.
- 5 18. Rambaut A, Holmes EC, O'Toole A, Hill V, McCrone JT, Ruis C, et al. A dynamic
- 6 nomenclature proposal for SARS-CoV-2 lineages to assist genomic epidemiology. Nat
- 7 Microbiol. 2020. doi: 10.1038/s41564-020-0770-5. PubMed PMID: 32669681.
- 8 19. Nguyen LT, Schmidt HA, von Haeseler A, Minh BQ. IQ-TREE: a fast and effective
- 9 stochastic algorithm for estimating maximum-likelihood phylogenies. Mol Biol Evol.
- 10 2015;32(1):268-74. Epub 2014/11/06. doi: 10.1093/molbev/msu300. PubMed PMID: 25371430;
- 11 PubMed Central PMCID: PMCPMC4271533.
- 12 20. Grubaugh ND, Gangavarapu K, Quick J, Matteson NL, De Jesus JG, Main BJ, et al. An
- amplicon-based sequencing framework for accurately measuring intrahost virus diversity using
- 14 PrimalSeq and iVar. Genome Biol. 2019;20(1):8. Epub 2019/01/10. doi: 10.1186/s13059-018-
- 15 1618-7. PubMed PMID: 30621750; PubMed Central PMCID: PMCPMC6325816.
- 16 21. Tchesnokova V, Kulasekara H, Larson L, Bowers V, Rechkina E, Kisiela D, et al.
- 17 Acquisition of the L452R Mutation in the ACE2-Binding Interface of Spike Protein Triggers
- 18 Recent Massive Expansion of SARS-CoV-2 Variants. Journal of clinical microbiology.
- 19 2021;59(11):e0092121. Epub 2021/08/12. doi: 10.1128/JCM.00921-21. PubMed PMID:
- 20 34379531; PubMed Central PMCID: PMCPMC8525575.
- 21 22. Genomic epidemiology of hCoV-19 [Internet]. 2020 [cited 16.09.1010]. Available from:
- 22 https://www.gisaid.org/epiflu-applications/hcov-19-genomic-epidemiology/.

- 1 23. Radukic MT, Brandt D, Haak M, Muller KM, Kalinowski J. Nanopore sequencing of
- 2 native adeno-associated virus (AAV) single-stranded DNA using a transposase-based rapid
- 3 protocol. NAR Genom Bioinform. 2020;2(4):lqaa074. Epub 2021/02/13. doi:
- 4 10.1093/nargab/lqaa074. PubMed PMID: 33575623; PubMed Central PMCID:
- 5 PMCPMC7671332.
- 6 24. Wick RR, Judd LM, Holt KE. Performance of neural network basecalling tools for
- 7 Oxford Nanopore sequencing. Genome Biol. 2019;20(1):129. Epub 2019/06/27. doi:
- 8 10.1186/s13059-019-1727-y. PubMed PMID: 31234903; PubMed Central PMCID:
- 9 PMCPMC6591954.

15

16

17

18

19

20

- 10 25. Bull RA, Adikari TN, Ferguson JM, Hammond JM, Stevanovski I, Beukers AG, et al.
- 11 Analytical validity of nanopore sequencing for rapid SARS-CoV-2 genome analysis. Nat
- 12 Commun. 2020;11(1):6272. Epub 2020/12/11. doi: 10.1038/s41467-020-20075-6. PubMed
- 13 PMID: 33298935; PubMed Central PMCID: PMCPMC7726558.

# 6 Tables

Sequencing metrics	Illumina	ONT
Number of samples	37	37
Alignment start and end positions	30 - 29842	54 - 29903
Mean Coverage depth	109	266
Total Number of reads	372,654	9741
Yielded bases	50,576,802	9,307,884
Fraction of bases aligned	0.928	0.897
Mean Read length	140	945
Average identity	99.6	91.4
Average PHRED score	32.35	10.78
No of SNPs	31	36
No of amino acid substitutions	22	25
No of deletions	14	15
No of Amino acid substitutions	22	25
No of frameshift mutations	0	2

% of ambiguous bases	9%	6%
No of samples with < 10% ambiguous bases	25	29
Successful Pangolin calls	31	34
Successful Scorpio calls	25	31
Run time (h) for 96 samples	26	14
Cost per sample (USD)	~150-250	~10-40

**Table 1.** Basic sequencing matrices for Illumina and Oxford Nanopore (ONT) outputs of 37 samples.

Figure legends

1

2

3

4

5

8

9

10

11

13

14

15

16

17

18

19

20

21

6 Figure 1. PHRED base call quality score distribution of samples sequenced by Illumina and

7 ONT. Distribution plot of PHRED (probability of error per base call in a log scale) quality score

(x axis) and error probability (secondary x axis) derived from the PHRED score for the data set

sequenced from Illumina (n=37) and ONT (n=37). The scores of ONT are shown in blue and

Illumina in red. The mean PHRED scores/error probability are shown with the dashed line for

each technology. The mean PHRED scores averaged at 32.35 in Illumina reads and 10.78 in

12 ONT.

Figure 2. Comparison of amino acid changes detected in SARS-CoV-2 genomes by both

sequencing technologies. Annotated amino acid substitutions and deletions detected in each

sample (n=37). Mutations colored in green indicates they are synonymously detected by both

sequencing technologies, whereas yellow and red indicate mutations detected exclusively by

only one technology. The X axis indicates each amino acid, which is denoted by the original

amino acid, its position in the protein and the substitution/deletion. Amino acid deletions are

denoted by "del".

Figure 3. Percentage of ambiguous bases (% of N) compared to the no of mutations (SNP)

**detected in each sample.** The trend between percentage of ambiguous bases is shown in the x

axis and number of mutations projected onto the consensus sequences is shown in the y axis.

The numbers displayed on each shape denotes the sample identification number (n=37)

sequenced by Illumina (red) or ONT (blue). Both technologies had detected a maximum SNPs

with 1% - 5% ambiguous bases. The consensus sequences generated by Illumina had a varying

percentage of ambiguous bases between 1% - 30%, whereas ONT sequencing generated either <

5% or more than 40% ambiguous bases due to its longer read lengths. Altogether ONT had

detected more SNPs than Illumina between of 1% - 5% ambiguous bases.

1

2

3

4

5

6

7

8

9

10

12

13

14

15

16

17

18

19

20

21

22

11 Figure 4. Combined maximum likelihood phylogenetic tree created using sequence pairs of

37 the samples. The ML tree was generated using the consensus sequences of each sequencing

technology with 1000 bootstrap replicates using TIM2+F+R2 model. Tree is rooted on SARS-

CoV-2 reference MN908947.3 and with samples sequences by Illumina coloured red and those

sequenced by ONT coloured blue. Bootstrap support values are shown on each branch. 21/37

samples coupled together with < 98% bootstrap support had > 90% genome coverage from both

Illumina and ONT datasets while 7/37 samples coupled together with less than 98% bootstrap

support. 9/37 of the samples which failed to couple with their counterpart from ONT or Illumina

had moderate to high (3% - 31%) ambiguous bases in either sequences.

Figure 5. Correlation of sub-consensus allele frequencies observed for SNV and Indels

between two sequencing technologies. The Correlation between sub-consensus single

nucleotide substitution frequencies observed for Illumina and ONT (a). Nucleotide substitutions detected exclusively by one technology only are indicated in green (Illumina) or blue (ONT) whereas the substitutions detected by both technologies are colored red. Even though more nucleotide substitutions exclusive to ONT were observed, there was a positive correlation  $(R^2=0.79)$  between two sequencing technologies. **b)** Correlation between sub-consensus indel frequencies observed for Illumina and ONT. More indels exclusive to ONT were seen with a weak correlation (R<sup>2</sup>=0.13) between the indel frequencies between two technologies suggesting ONT tend to result in more false-positive indels.









